A detailed history of Mariner, LLC transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Mariner, LLC holds 8,860 shares of TVTX stock, worth $305,670. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,860
Previous 11,128 20.38%
Holding current value
$305,670
Previous $164,000 28.66%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

SELL
$14.61 - $27.31 $33,135 - $61,939
-2,268 Reduced 20.38%
8,860 $211,000
Q2 2025

Aug 14, 2025

SELL
$13.49 - $21.54 $8,579 - $13,699
-636 Reduced 5.41%
11,128 $164,000
Q1 2025

May 15, 2025

BUY
$17.07 - $23.75 $9,507 - $13,228
557 Added 4.97%
11,764 $210,000
Q4 2024

Feb 13, 2025

BUY
$13.65 - $19.85 $1,515 - $2,203
111 Added 1.0%
11,207 $195,000
Q3 2024

Nov 13, 2024

BUY
$7.89 - $15.21 $87,547 - $168,770
11,096 New
11,096 $155,000

Others Institutions Holding TVTX

About Travere Therapeutics, Inc.


  • Ticker TVTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 64,173,600
  • Market Cap $2.21B
  • Description
  • Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...
More about TVTX
Track This Portfolio

Track Mariner, LLC Portfolio

Follow Mariner, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mariner, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mariner, LLC with notifications on news.